Document:

<PAGE>

                                                                    EXHIBIT 10.8

          CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
        SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

                                LICENSE AGREEMENT

         This License Agreement (the "Agreement") is effective as of December
31, 2001 (the "Effective Date") between ISIS PHARMACEUTICALS, INC., a Delaware
corporation having an address at 2292 Faraday Avenue, Carlsbad, CA ("Isis") and
EYETECH PHARMACEUTICALS, INC., a corporation having an address at 666 Fifth
Avenue, 35th Floor, New York, NY 10103 ("EyeTech").

                                    ARTICLE 1
                                   DEFINITIONS

         Capitalized terms used herein have the meaning set forth in Exhibit A.

                                    ARTICLE 2
                                SCOPE OF LICENSE

2.1      Grant. Subject to the terms of this Agreement and during the Term, Isis
grants to EyeTech a non-exclusive license under the Licensed Patent Rights to
make, have made, use and sell EYE001 worldwide. The license is sublicensable.

                                    ARTICLE 3
                           LICENSE FEES AND ROYALTIES

         3.1      Fees and Royalties. EyeTech will pay to Isis the fees,
milestones and royalties set forth in this Article 3.

                  3.1.1    License Fees. EyeTech will pay an initial,
irrevocable and non-refundable license fee of $2,000,000 (the "License Fee") to
Isis, $1,000,000 of which will be paid upon execution of this Agreement and
$1,000,000 of which will be paid upon the earlier of (i) the date of the AMD
Completed Patient Enrollment, or (ii) July 31, 2002.

                  3.1.2    Milestones. EyeTech will pay the following milestones
to Isis:

                           a.       For the initial indication of age-related
                                    macular degeneration for EYE001:
                                    [**]

                           b.       For each additional therapeutic indication
                                    for EYE001:
                                    [**]

<PAGE>

                                       2                        [EXECUTION COPY]

                  3.1.3    Royalties on EYE001. EyeTech will pay Isis a royalty
of [**] on Net Sales of EYE001 when the manufacture, use or sale of EYE001 would
infringe the Licensed Patent Rights.

                                    ARTICLE 4
                              PAYMENTS AND REPORTS

         4.1      Payment. Royalty payments will be due every three (3) months
beginning with the first commercial sale of EYE001 (each such 3-month period a
"Reporting Period") and will be paid within sixty (60) days of the close of each
Reporting Period. Each royalty payment will be accompanied by a statement of the
amount of Net Sales and all adjustments thereto during such Reporting Period.

         4.2      Mode of Payment. EyeTech will make all payments required under
this Agreement in U.S. Dollars. The payments due on the sale of EYE001 received
outside the United States will be translated using exchange rates published in
the Wall Street Journal on the last day of the Reporting Period in question.

         4.3      Records Retention. EyeTech and its sublicensees will keep
complete and accurate records pertaining to the sale of EYE001 and covering all
transactions from which the Net Sales are derived for a period of thirty-six
(36) months after the year in which such Net Sales were received, and in
sufficient detail to permit Isis to confirm the accuracy of royalty calculations
hereunder.

         4.4      Audit Request. No more than once each calendar year and at the
request of Isis, EyeTech will permit an independent, certified public accountant
appointed by Isis and acceptable to EyeTech, at reasonable times and upon
reasonable notice, to examine those records and all other material documents
relating to or relevant to Net Sales in the possession or control of EyeTech,
for a period of two (2) years after such royalties have accrued, as may be
necessary to: (a) determine the correctness of any report or payment made under
this Agreement; or (b) obtain information as to the royalties payable for any
Reporting Period in the case of EyeTech's failure to report or pay pursuant to
this Agreement. Said accountant will not disclose to Isis any information other
than information relating to said reports, royalties, and payments and will
disclose such information in a format agreed upon by the parties that will
ensure that no confidential information of EyeTech is disclosed. Results of any
such examination will be made available to both parties. The fees charged by the
public accountant conducting the audit will be paid for by Isis, provided that,
if the audit determines that the additional royalties payable by EyeTech for an
audited period exceed [**] of the royalties actually paid for such period, then
EyeTech will pay the fees and expenses charged by such accounting firm.

<PAGE>

                                       3                        [EXECUTION COPY]

                                    ARTICLE 5
                      PATENTS, INFRINGEMENT AND ENFORCEMENT

         5.1      Patent Prosecution and Maintenance. Isis will have the right
and responsibility to prosecute and/or maintain the Licensed Patent Rights in
any country at its own expense. If ISIS decides to discontinue the prosecution
or maintenance of any Licensed Patent Right entirely or in a particular
country, it will inform EyeTech thereof with sufficient time for EyeTech to
assume the prosecution or maintenance of such Licensed Patent Right, and EyeTech
may assume such prosecution or maintenance if such Licensed Patent Right
provides a substantial competitive advantage to EyeTech with respect to EYE001
in the applicable country. If Isis has granted similar rights to third parties,
EyeTech's rights under this section 5.1 will be shared equally with such third
parties.

                                    ARTICLE 6
                         REPRESENTATIONS AND WARRANTIES

         6.1      Isis Representation and Warranty. Isis warrants that it has
the lawful right to grant the license made the subject of this Agreement. Except
as expressly stated in this section, Isis makes no other representations of any
kind or nature whatsoever. ISIS MAKES NO WARRANTIES OR REPRESENTATIONS, EXPRESS
OR IMPLIED, INCLUDING BUT NOT LIMITED TO, WARRANTIES OF FITNESS FOR A PARTICULAR
PURPOSE OR MERCHANTABILITY OR NONINFRINGEMENT REGARDING OR WITH RESPECT TO THE
LICENSED PATENTS. Without limiting the generality of the foregoing, nothing in
this Agreement will be construed as (a) a warranty or representation by Isis as
to validity or scope of the Licensed Patent Rights or (b) a warranty or
representation that anything made, used, sold or otherwise disposed of under the
license is or will be free from infringement of third party rights.

         6.2      EyeTech Representations and Warranties. EyeTech represents and
warrants to Isis that EyeTech has the power and authority to execute, deliver
and perform this Agreement, and this Agreement is a valid and binding obligation
of EyeTech, enforceable in accordance with its terms.

                                    ARTICLE 7
                                    INDEMNITY

         7.1      EyeTech agrees to indemnify, hold harmless and defend Isis,
its officers, directors, employees and agents, from and against any and all
claims, suits, losses, damages, costs, fees and expenses (collectively,
"Claims") resulting from or arising out of (a) the development, manufacture,
storage, sale or other distribution or any other use of EYE001 by EyeTech, its
affiliates, sublicensees, agents and representatives or use by end users and
other third parties of EYE001; and (b) EyeTech's breach of any representation or
warranty herein.

         7.2      In all cases where Isis seeks indemnification from EyeTech
under this Article 7, Isis will promptly notify EyeTech of receipt of any claim
or lawsuit covered by

<PAGE>

                                       4                        [EXECUTION COPY]

such indemnification obligation and will cooperate fully with EyeTech in
connection with the investigation and defense of such claim or lawsuit. EyeTech
will have the right to control the defense, with counsel of its choice, provided
that Isis will have the right to be represented by advisory counsel at its own
expense. Neither party will settle or dispose of the matter in any matter that
could negatively and materially affect the rights or liability of the other
party without the prior written consent of such party, which will not be
unreasonably withheld or delayed.

                                    ARTICLE 8
                              TERM AND TERMINATION

         8.1      Term. This Agreement will commence as of the Effective Date
and continue until the last Licensed Patent Rights expire (the "Term").

         8.2      Termination for Breach. Notwithstanding anything to the
contrary herein, a party may terminate this Agreement in the event that the
other party (the "Defaulting Party") materially breaches its obligations
hereunder and fails to cure such breach within ninety (90) days of receipt of
written notice thereof (which notice will specify the breach in reasonable
detail and demand it be cured) (or, if such breach cannot be cured in such
ninety (90) day period, if the Defaulting Party does not commence and diligently
continue (until completed) actions to cure such default). Such termination will
be without prejudice to the non-Defaulting Party's other rights under this
Agreement, or any of its other rights or remedies available to it by law or in
equity.

         8.3      Termination by EyeTech. Notwithstanding anything contained
herein to the contrary, EyeTech has the right to terminate this Agreement at any
time in its sole discretion by giving ninety (90) days advance written notice to
ISIS; provided, that at the time of such termination EyeTech is not conducting
(and does not intend to conduct) itself in a manner that would, but for the
license granted in Article 2 of this Agreement, infringe the Licensed Patent
Rights. In the event of such termination by EyeTech, EyeTech will still be
obligated to pay any amounts due to Isis hereunder which, but for the lapse of
time, will be owed to Isis, including the unpaid portion of the License Fee.
Notwithstanding Section 3.1.1 above, any unpaid portion of the License Fee will
be immediately due and payable upon such termination.

         8.3      Effect of Termination. Upon the termination of this Agreement
for any reason, all rights licensed to EyeTech will revert to Isis.

         8.4      Accrued Rights, Surviving Rights and Obligations. Termination
or expiration of this Agreement for any reason will be without prejudice to any
rights that will have accrued to the benefit of either party prior to such
termination or expiration. Such termination or expiration will not relieve
either party from obligations that are expressly indicated to survive
termination or expiration of this Agreement including, without limitation,
EyeTech's obligation to pay all royalties that will have accrued hereunder.
Without limiting the foregoing, the parties' rights and obligations under
Articles 4, 6 and 7, and section 8.3 will likewise survive termination or
expiration of this Agreement.

<PAGE>

                                       5                        [EXECUTION COPY]

                                    ARTICLE 9
                                  MISCELLANEOUS

         9.1      Relationship of the Parties. Nothing in this Agreement is
intended to create, or creates, a partnership or joint venture relationship
between the parties. The relationship between the parties hereunder is that of
independent contractors.

         9.2      Successors and Assigns. Except as otherwise provided herein,
this Agreement may not be assigned by a party without the prior written consent
of the other, provided, however, that either party may assign this Agreement to
any successor by merger or to the purchaser of all or substantially all of its
assets provided that the party will remain liable and responsible for the
performance and observance of all of its duties and obligations hereunder.
Nothing in this Agreement, express or implied, is intended to confer upon any
party other than the parties hereto or their respective permitted successors and
assigns any rights, remedies, obligations or liabilities under this Agreement.

         9.3      Governing Law. This Agreement will be governed by and
construed under the laws of the State of Delaware without giving effect to its
conflict of laws rules.

         9.4      Counterparts. This Agreement may be executed in two or more
counterparts, each of which will be decreed an original, but all of which
together will constitute one and the same instrument.

         9.5      Compliance With Laws. Both parties will comply with all
applicable laws, rules and regulations pertaining to the development, testing,
manufacture, marketing and import or export of EYE001 and will, as appropriate,
include similar provisions in any sublicense agreements requiring sublicensees
to do the same.

         9.6      Notices. Unless otherwise provided, any notice required or
permitted under this Agreement will be given in writing and will be deemed
effectively given upon personal delivery to the party to be notified or five (5)
days after upon deposit with the United States Post Office by registered or
certified mail, postage prepaid or through a major courier (such as Federal
Express, DHL or UPS), or sent by facsimile, and addressed to the party to be
notified at the address set forth below.

To Isis:                            Isis Pharmaceuticals, Inc.
                                    2292 Faraday Avenue
                                    Carlsbad, CA 92008
                                    Attn: Executive Vice President
                                    Fax: 760-931-3861
                                    Phone: 760-603-2707

with copies to:                     General Counsel
                                    Fax: 760-603-3820

<PAGE>

                                       6                        [EXECUTION COPY]

To EyeTech:                         Eyetech Pharmaceuticals, Inc.
                                    666 Fifth Avenue
                                    35th Floor
                                    New York, NY 10103
                                    Attn: Chief Executive Officer

with copies to:                     General Counsel

         9.7      Amendments and Waivers. Any term of this Agreement may be
amended and the observance of any term of this Agreement may be waived (either
generally or in a particular instance and either retroactively or
prospectively), only with the written consent of Isis and EyeTech. The waiver by
either of the parties of any breach of any provision hereof by the other party
shall not be construed to be a waiver of any succeeding breach of such provision
or a waiver of the provision itself.

         9.8      Severability. If one or more provisions of this Agreement are
held to be unenforceable under applicable law, such provision will be excluded
from this Agreement and the balance of the Agreement will be interpreted as if
such provision were so excluded and will be enforceable in accordance with its
terms.

         9.9      Force Majeure. No party will be deemed to be in default of
this Agreement to the extent the performance of its obligations or attempts to
cure any breach are delayed or prevented by reason of any act of God, war, fire,
natural disaster, accident, act of government, or any other cause beyond the
reasonable control of such party, if the party affected will give prompt notice
of any such event to the other party. In the event of such a force majeure
event, the time for performance or cure will be extended for the period equal to
the duration of such force majeure event but not in excess of six (6) months.

         9.10     Entire Agreement. This Agreement is the entire agreement of
the parties with respect to the subject matter hereof, and any previous
agreements, discussions or understandings, whether written or oral, are hereby
merged herein.

<PAGE>

                                       7                        [EXECUTION COPY]

         IN WITNESS WHEREOF, the parties have executed this Agreement as of the
Effective Date.

ISIS PHARMACEUTICALS, INC.                   EYETECH PHARMACEUTICALS, INC.

By: /s/ B. Lynne Parshall                    By: /s/David Guyer
    ---------------------------------            -------------------------------

Name: B. Lynne Parshall                      Name: David Guyer

Title: Executive Vice President              Title: CEO

<PAGE>

                                       8                        [EXECUTION COPY]

                                    EXHIBIT A
                                   DEFINITIONS

1.   "AMD Completed Patient Enrollment" means the completion of enrollment of
     that number of patients in Eyetech's Pivotal Phase II/III clinical trial
     program that is necessary to gain Food and Drug Administration regulatory
     approval of EYE001 for the treatment of the wet form of age-related macular
     degeneration.

2.   "Major Market" means Canada, any European Community member country, Japan
     or the United States.

3.   "Manufacturing Process" means the process steps [**] set forth in master
     batch records for EYE001 in the version existing as of the Effective Date,
     including reasonable minor variants and extensions of process steps
     thereof.

4.   "Net Sales" will mean the gross invoice price of EYE001 sold by EyeTech,
     its affiliates and sublicensees to a third party less the following items:
     (i) trade discounts, credits or allowances, (ii) credits or allowances
     additionally granted upon returns, rejections or recalls (except where any
     such recall arises out of EyeTech's or sublicensee's gross negligence,
     willful misconduct or fraud), (iii) freight, shipping and insurance
     charges, (iv) taxes, duties or other governmental tariffs (other than
     income taxes) and (v) government-mandated rebates. EyeTech, its affiliates
     or sublicensees will be treated as having sold EYE001 for an amount equal
     to the fair market value of EYE001 if: (a) EYE001 is used by EyeTech, its
     affiliates or sublicensees without charge or provision of invoice, or (b)
     EYE001 is provided to a third party by EyeTech, its affiliates or
     sublicensees without charge or provision of invoice and used by such third
     party.

5.   "EYE001" means EyeTech's EYE001 NX1838 non-antisense therapeutic product
     (or any product containing EyeTech's EYE001 NX1838 non-antisense
     therapeutic product for the treatment of ophthalmic conditions. EYE001 will
     also include any minor chemical modification to EYE001 NX1838.

6.   "Patent" or "Patents" means (a) patent applications (including provisional
     applications and applications for certificates of invention); (b) any
     patents issuing from such patent applications (including certificates of
     invention); (c) all patents and patent applications based on, corresponding
     to, or claiming the priority date(s) of any of the foregoing; and (d) any
     substitutions, extensions (including supplemental protection certificates),
     registrations, confirmations, reissues, divisionals, continuations,
     re-examinations, renewals and foreign counterparts thereof.

7.   "Licensed Patent Rights" means all Patents owned by Isis or controlled by
     Isis through the Term which Isis has the right to sublicense with no
     obligation to any third party, which claim or cover [**].

8.   "Reporting Period" has the meaning set forth in Section 4.1.

9.   "Term" has the meaning set forth in Section 8.1.<PAGE>
                                                                   EXHIBIT 10.23

          CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
        SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

                       MANUFACTURING AND SUPPLY AGREEMENT

      This MANUFACTURING AND SUPPLY AGREEMENT (the "Agreement") dated as of
November 11, 2003 (the "Effective Date") is made by and between Raylo Chemicals
Inc., a Canadian corporation ("Raylo") and Eyetech Pharmaceuticals, Inc., a
Delaware corporation ("Eyetech").

                                    RECITALS

      WHEREAS, Eyetech develops and commercializes new drugs to reduce and
prevent serious vision loss caused by eye disease and to develop new
technologies to safely deliver drugs to the back of the eye;

      WHEREAS, Raylo is a contract manufacturer of chemical compounds for human
drugs;

      WHEREAS, Raylo and Eyetech wish to enter into an agreement describing the
terms and conditions upon which Raylo will manufacture and supply to Eyetech,
and Eyetech will purchase from Raylo, the active pharmaceutical ingredient in
Eyetech's Macugen(TM) product;

      WHEREAS, Raylo and Eyetech wish to set forth certain license terms
pursuant to which Raylo will license and sublicense its intellectual property to
permit Eyetech to manufacture for itself or have manufactured by a third party
manufacturer the same product;

      WHEREAS, Raylo and Eyetech are parties to a certain Letter of
Understanding dated September 1, 2003 (the "LOU") that, during the effectiveness
of such LOU, will supersede and/or modify certain terms of this Agreement; and

      WHEREAS, Raylo and Eyetech are parties to a certain Quality Agreement
dated November 11, 2003 (the "Quality Agreement"), which sets forth certain
agreements of the Parties regarding quality control and quality assurance;

      NOW, THEREFORE, in consideration of the foregoing recitals and the mutual
promises, covenants and agreements hereinafter set forth the parties hereto
agree as follows:
<PAGE>
                                 1. DEFINITIONS

      1.1 "15mM Process" shall mean the process for manufacturing API
established, validated and documented through the 15mM Process Validation
Procedures.

      1.2 "15mM Process Validation Procedures" shall mean the procedures for
validation of the 15mM Process set forth in the Quality Agreement.

      1.3 "Affiliate" shall mean, with respect to a Party, any Person that
controls, is controlled by, or is under common control with such Party. For
purposes of this Section 1.3, "control" shall refer to (a) in the case of a
Person that is a corporate entity, direct or indirect ownership of fifty percent
(50%) or more of the stock or shares having the right to vote for the election
of directors of such Person and (b) in the case of a Person that is an entity,
but is not a corporate entity, the possession, directly or indirectly, of the
power to direct, or cause the direction of, the management or policies of such
Person, whether through the ownership of voting securities, by contract or
otherwise.

      1.4 "Agreement" shall mean this Manufacturing and Supply Agreement between
Raylo and Eyetech together with the recitals and all exhibits, schedules and
attachments hereto.

      1.5 "Amgen License Fee" shall mean a fee in the amount of US$[**] payable
by Eyetech to Raylo upon exercise by Eyetech of its option to license the Amgen
Patents in accordance with Section 2.3(a).

      1.6 "Amgen Patents" shall mean U.S. Patent No. 4,762,779 and Canadian
Patent No. 1,303,526 and all Patent Rights based on such patents, and all
counterparts of any of the foregoing in any country.

      1.7 "API" shall mean active pharmaceutical ingredient bulk drug substance
manufactured for use in the Eyetech Product, as described in the Specifications.

      1.8 "Applicable Legal Requirements" shall mean: (a) any and all federal,
national, supranational, state and local laws, regulations, ordinances, orders
and requirements applicable to the activities under this Agreement; and (b) any
other specifications, guidelines, procedures and directives mutually agreed to
by the Parties, applicable to the API or Eyetech Product, or activities under
this Agreement, including, without limitation, cGMP.

      1.9 "Batch" shall mean a batch of API resulting from the 15mM Process.

      1.10 "[**]" shall mean [**].

      1.11 "Binding Order" shall have the meaning set forth in Section 3.2(b)
hereof.

      1.12 "Business Day" shall mean a day on which banks are open for business
in both New York, New York and Edmonton, Alberta.

                                       2
<PAGE>
      1.13 "Certificates" means, with respect to the API, all necessary
certificates of analysis and/or certificates of compliance.

      1.14 "CFR" shall mean the United States Code of Federal Regulations.

      1.15 "cGMP" shall mean applicable current Good Manufacturing Practices as
described, without limitation, in ICHQ7A as specified in the Quality Agreement.

      1.16 "Confidential Information" shall mean all Know How or other
information (whether or not patentable) regarding a Party's technology,
products, business information or objectives, and all biological materials of a
Party. Notwithstanding the foregoing, Confidential Information shall not include
Know-How or other information that:

            (a) was known or used by the receiving Party or its Affiliates prior
to its date of disclosure to the receiving Party; or

            (b) either before or after the date of the disclosure to the
receiving Party is lawfully disclosed to the receiving Party or its Affiliates
by sources other than the disclosing Party rightfully in possession of such
Know-How or other information and not bound by confidentiality obligations to
the disclosing Party; or

            (c) either before or after the date of the disclosure to the
receiving Party or its Affiliates is or becomes published or otherwise is or
becomes part of the public domain through no breach hereof on the part of the
receiving Party or its Affiliates; or

            (d) is independently developed by or for the receiving Party or its
Affiliates without reference to or reliance upon the Confidential Information of
the disclosing Party as demonstrated by written records.

      1.17 "Delivery" and all variations of this term means the delivery to
Eyetech of API, FCA (Incoterms 2000) the Facility, together with all applicable
Certificates, that meets the Specifications and has been manufactured in
accordance with cGMP.

      1.18 "Dollars" or "$" shall mean Canadian Dollars unless expressly
provided otherwise.

      1.19 "Effective Date" shall have the meaning set forth in the introduction
hereto.

      1.20 "Eyetech Intellectual Property" shall mean all Eyetech Know-How and
Eyetech Patent Rights.

      1.21 "Eyetech Know-How" shall mean any Know-How that (a) either (i) is in
Eyetech's and/or its Affiliates' possession on the Effective Date or (ii)
Eyetech and/or its Affiliates develop or acquire during the Term and (b) is
owned or controlled by, or licensed to, Eyetech and/or its Affiliates and to
which Eyetech and/or its Affiliates have

                                       3
<PAGE>
the right to grant licenses or sublicenses without violating the terms of any
agreement with a third party.

      1.22 "Eyetech Materials" shall mean the raw materials to be supplied to
Raylo by Eyetech pursuant to Section 3.3 hereof. A list of all Eyetech Materials
is attached hereto as Exhibit B.

      1.23 "Eyetech Patent Rights" shall mean Patent Rights that (a) cover
Eyetech Know-How and (b) are owned or controlled by, or licensed to, Eyetech
and/or its Affiliates and to which Eyetech and/or its Affiliates have the right
to grant licenses or sublicenses without violating the terms of any agreement
with a third party.

      1.24 "Eyetech Product" shall mean Eyetech's product named "Macugen(TM)"
delivered by intravitreal injection.

      1.25 "Facility" shall mean Raylo's facility at 1021 Hayter Road, Edmonton,
Alberta, Canada or such other manufacturing facility of Raylo or its Affiliates
as may be approved by Eyetech.

      1.26 "FD&C Act" shall mean the United States Federal Food, Drug, and
Cosmetic Act, as amended, and the regulations promulgated thereunder.

      1.27 "FDA" shall mean the United States Food and Drug Administration.

      1.28 "Forecast" shall have the meaning set forth in Section 3.2(a) hereof.

      1.29 "Improvement" shall mean any upgrade, new version, adaptation,
change, redesign, improvement, derivative work, modification or development of
or to the API, the Specifications, or the method or process of manufacture,
production or use of the API, conceived or reduced to practice, or otherwise
created, in the course of the Parties' activities pursuant to this Agreement.

      1.30 "Initial Term" shall have the meaning set forth in Section 9.1.

      1.31 "Know-How" shall mean all information, inventions, discoveries,
copyrights, trade secrets, data or materials, whether proprietary or not, and
all Improvements.

      1.32 "LOU" shall have the meaning set forth in the recitals hereto.

      1.33 "LOU Termination Date" shall mean the date that the interim
provisions of the LOU relating to the processing of API at the Facility and
responsibility for rejected Batches shall, by agreement of the Parties in
accordance with Section 4.1(c), terminate.

      1.34 "Material Safety Data Sheet" means the material safety data sheet
used to comply with the United States Occupational Safety and Health
Administration's Hazard Communication Standard, 29 CFR Section 1910.120, as
amended from time to time.

                                       4
<PAGE>
      1.35 "Minimums" shall mean the percentages of Eyetech's requirements for
API used in the Eyetech Product set forth on Exhibit C hereto.

      1.36 "mM" shall mean one-thousandth of a Mole.

      1.37 "Negotiated Per Gram Cost" shall mean the cost per gram of API to be
paid by Eyetech to Raylo set forth on Exhibit D, as adjusted from time to time
in accordance with Section 4.2.

      1.38 "PAI" shall mean a pre-approval inspection of the Facility to
demonstrate the requirements of Section 505 of the FD&C Act are met with regard
to the methods used in, and the facilities and controls used for, the
manufacture and processing of a drug.

      1.39 "Parties" shall mean Raylo and Eyetech together and "Party" shall
mean either Raylo or Eyetech individually.

      1.40 "Patent Rights" shall mean all patents and patent applications
(including any continuations and continuations-in-part of any such patent
applications, and any divisionals, provisionals or substitute applications with
respect to any such patent applications), any patent issued with respect to any
such patent applications, any reissue, reexamination, renewal or extension
(including any supplemental patent certificate) of any such patent, and any
confirmation patent or registration patent or patent of addition based on any
such patent, and all counterparts of any of the foregoing in any country.

      1.41 "Person" shall mean any natural person or any corporation, company,
partnership, joint venture, firm or other entity, including without limitation a
Party.

      1.42 "Quality Agreement" shall have the meaning set forth in the recitals
hereto.

      1.43 "Raw Materials" means ingredients, additives, purification resins,
and reagents, and any other components or in-process materials as defined in 21
CFR Section 210.3, which are purchased by Raylo for use in the manufacture of
the API, but not including the Eyetech Materials.

      1.44 "Raylo Intellectual Property" shall mean all Raylo Know-How and Raylo
Patent Rights.

      1.45 "Raylo Know-How" shall mean any Know-How that (a) either (i) is in
Raylo's and/or its Affiliates' possession on the Effective Date or (ii) Raylo
and/or its Affiliates develop or acquire during the Term and (b) is owned or
controlled by, or licensed to, Raylo and/or its Affiliates and to which Raylo
and/or its Affiliates have the right to grant licenses or sublicenses without
violating the terms of any agreement with a third party.

      1.46 "Raylo Patent Rights" shall mean Patent Rights that (a) cover Raylo
Know-How and (b) are owned or controlled by, or licensed to, Raylo and/or its
Affiliates

                                       5
<PAGE>
and to which Raylo and/or its Affiliates have the right to grant licenses or
sublicenses without violating the terms of any agreement with a third party.

      1.47 "Services" shall have the meaning set forth in Section 3.6.

      1.48 "Specifications" shall mean the initial specifications for the API
set forth on Exhibit A hereto, and any subsequent changes or modifications to
the initial specifications as determined by Eyetech from time to time.

      1.49 "Term" shall mean the Initial Term as it may be extended pursuant to
Section 9.1 hereof.

      1.50 "Validation Batches" shall mean Batches of API submitted by Raylo to
Eyetech for validation of the 15mM Process pursuant to the Quality Agreement.

                 2. VALIDATION; REGULATORY COMPLIANCE; LICENSES

      2.1 Validation. Validation of the 15mM Process shall be conducted as set
forth in the Quality Agreement. All post-validation changes to the 15mM Process
shall require the prior written approval of Eyetech.

      2.2 Regulatory Compliance and Records.

            (a) Regulatory Inspections and Notices. Raylo is responsible for
passing any required PAI in connection with Eyetech's application for regulatory
approval of the Eyetech Product. Eyetech shall provide a third party consultant,
at its cost, to advise Raylo on what steps are necessary for Raylo to pass any
such PAI with respect to the API in the Facility. Raylo shall provide Eyetech
with a copy of all inspection results, including a copy of any inspection report
and/or observations from the regulatory authority (or its designee) for any
regulatory inspection; provided that Raylo may redact any third party
confidential information from such inspection results if such third party
confidential information is not relevant to a complete understanding of the
impact of the regulatory inspection on Raylo's ability to manufacture and supply
API in accordance with this Agreement. Raylo shall notify Eyetech within two (2)
Business Days after receiving formal notice about the initiation of any
compliance or enforcement action, investigation, inspection, review or inquiry
by the FDA or other regulatory authority concerning the API, including any Form
483, recall, seizure, warning letter, or court complaint. In addition, Eyetech
shall have the right to have, at Eyetech's option, up to two (2) Eyetech
representatives present at the Facility for any regulatory inspection that
relates to the manufacture of the API.

            (b) Access to Records. Eyetech shall have access to all records,
documents and materials of Raylo relating to this Agreement and the manufacture
of the API. Upon Eyetech's request and at Eyetech's cost, Raylo shall promptly
deliver to Eyetech a single copy of any such records, documents and materials
that Eyetech may request.

                                       6
<PAGE>
            (c) Regulatory Submissions and Support. Raylo shall cooperate with
Eyetech and provide Eyetech with any information in Raylo's possession that
Eyetech requires in order to make submissions to regulatory authorities relating
to the API and/or the Eyetech Product. Eyetech will advise Raylo from time to
time of any regulatory submissions relating to the API and/or the Eyetech
Product requiring responses from Raylo. Raylo shall respond to any such inquiry
and provide all requested information promptly after Raylo's receipt of the
inquiry, and Raylo shall provide Eyetech with notice of any inquiry from a
regulatory authority within two (2) Business Days from Raylo's receipt of the
inquiry.

      2.3 Licenses; Covenants.

            (a) License Under Amgen Patents. Raylo hereby grants to Eyetech an
irrevocable, perpetual, non-exclusive, worldwide, royalty-free license, with the
right to grant sublicenses to Eyetech's Affiliates and to Pfizer Inc. and Pfizer
Inc.'s affiliates, under the Amgen Patents, solely to make, have made, use,
sell, offer for sale and import the API and Eyetech Product, effective upon
written notice from Eyetech to Raylo that it is exercising its option to license
the Amgen Patents and payment by Eyetech to Raylo of the Amgen License Fee.
Raylo hereby agrees not to transfer or grant to any third party any rights in
the Amgen Patents that would prevent or are inconsistent with the foregoing
license grant to Eyetech.

            (b) License Under Eyetech Intellectual Property. Eyetech hereby
grants to Raylo a non-exclusive, worldwide, non-sublicensable, royalty-free
license under the Eyetech Intellectual Property during the Term solely to
perform Raylo's obligations under this Agreement.

            (c) License Under Raylo Intellectual Property. In order to ensure
that Eyetech will be free to continue using, or having used, its manufacturing
processes and other technology relating to the API and the Eyetech Product both
during the Term and after the expiration or termination of this Agreement, Raylo
hereby grants to Eyetech an irrevocable, perpetual, non-exclusive, worldwide,
royalty-free license, with the right to grant sublicenses to Eyetech's
Affiliates and to Pfizer Inc. and Pfizer Inc.'s Affiliates, under the Raylo
Intellectual Property, solely to make, have made, use, sell, offer for sale and
import the API and Eyetech Product.

            (d) Covenants Regarding [**]. Raylo hereby agrees (i) to [**] in
full force and effect during the Term and thereafter for a period of [**], (ii)
agrees not to take any action or omit to take any action, which action or
omission could result in [**] and (iii) agrees to notify Eyetech within two (2)
Business Days of receiving any communication from or on behalf of [**]. Upon
request by Eyetech, and at Eyetech's expense or [**], Raylo shall exercise its
right under Section 2.02 of the [**] that are [**] those of the [**] designated
by Eyetech.

      2.4 Ownership of and Licenses to Improvements. Each Party shall own all
Improvements made by it or its employees. Raylo hereby grants to Eyetech an
irrevocable, perpetual, exclusive, worldwide, royalty-free license, with the
right to grant

                                       7
<PAGE>
sublicenses, to all Improvements made by Raylo and its employees, solely to
make, have made, use, sell, offer for sale and import the API and Eyetech
Product. Eyetech hereby grants to Raylo an irrevocable, perpetual,
non-exclusive, worldwide, royalty-free license, with the right to grant
sublicenses, to manufacturing method or process Improvements made by Eyetech and
its employees, solely for purposes unrelated to the making, having made, using,
sale, offer for sale or importation of the API or the Eyetech Product.

      2.5 Upgrade to Manufacturing Process. If Eyetech requests that Raylo
upgrade its manufacturing process for the API from the 15mM Process to a higher
volume process (e.g., to a 100mM process), the Parties shall in good faith
cooperate to make any operational changes necessary to implement such upgrade
and to amend this Agreement, including without limitation the validation and
pricing provisions hereof, as reasonably necessary to accommodate such necessary
changes.

           3. SUPPLY OF PRODUCT; EYETECH MATERIALS; SERVICES; ADVERSE
                         EXPERIENCE REPORTING; FACILITY

      3.1 Supply and Purchase of API. Raylo shall manufacture API exclusively
for and sell API exclusively to Eyetech and its Affiliates and, if requested by
Eyetech, to Pfizer Inc. and its affiliates, and Eyetech (together with its
Affiliates, Pfizer Inc. and Pfizer Inc.'s affiliates) shall purchase from Raylo
quantities of the API sufficient to meet Eyetech's Minimum obligations; provided
that Eyetech shall not be obligated to purchase such Minimums from Raylo if its
failure to do so is related to Raylo's failure to accept Eyetech's Binding
orders or to Deliver API to Eyetech by the requested delivery dates in Eyetech's
Binding Orders. If Eyetech requests that Raylo sell API to Pfizer Inc. and
Pfizer Inc.'s affiliates, Eyetech hereby guarantees to Raylo payment by Pfizer
Inc. and Pfizer Inc.'s affiliates for API Delivered by Raylo in accordance with
written orders placed by Pfizer Inc. and Pfizer Inc.'s affiliates.

      3.2 Production Planning; Forecasts.

            (a) Forecast. During the Term, Eyetech shall provide to Raylo,
within the first month of each quarter, on a quarterly basis, a rolling forecast
for orders of API with respect to the following four (4) quarters (each, a
"Forecast"). Eyetech shall be obligated to purchase at least [**] of the amount
of API forecast for the first quarter of any Forecast, and shall execute a
binding purchase order to that effect. The forecast for the remaining three (3)
quarters of any Forecast shall be non-binding.

            (b) Binding Orders. The binding portions of the Forecasts and
Eyetech's purchase orders for quantities in excess of such binding portions
shall be binding (each, a "Binding Order" and, collectively, "Binding Orders").

            (c) Obligation to Supply

                  (1) Raylo shall (A) fill all Binding Orders, (B) Deliver API
                  ordered thereunder, (C) use best efforts to accommodate
                  Eyetech's requested Delivery dates, and (D) in any case
                  Deliver such API within the quarter, for up to [**]% of
                  Eyetech's requirements

                                       8
<PAGE>
                  forecasted for the first quarter in the most recent Forecast
                  preceding such Binding Orders, provided that Eyetech submits
                  purchase orders for such Binding Orders at least [**] days
                  preceding the requested Delivery date and provided further
                  that Eyetech acknowledges that if, despite Raylo's best
                  efforts to accommodate Eyetech's requested Delivery dates,
                  Raylo is unable to fully accommodate such requested Delivery
                  dates due to [**], then Raylo shall not be in breach of its
                  obligations pursuant to clause (C) above as long as Raylo
                  continues to use its best efforts to Deliver the API ordered
                  by Eyetech as close as reasonably practicable to Eyetech's
                  requested Delivery dates. In addition, Raylo shall use best
                  efforts to fill all Binding Orders, and Deliver API ordered
                  thereunder by the requested Delivery date, for quantities in
                  excess of [**]% of Eyetech's requirements forecasted for the
                  first quarter in the most recent Forecast preceding such
                  Binding Orders, provided that Eyetech submits purchase orders
                  for such Binding Orders at least [**] days preceding the
                  beginning of the quarter in which Delivery is requested.

                  (2) If Raylo is unable to supply the API ordered by Eyetech
                  hereunder and Raylo is unable to remedy the problem within
                  [**] days after its initial failure to supply, then thereafter
                  Eyetech's Minimum obligations hereunder shall no longer apply;
                  provided that Eyetech shall in good faith discuss with Raylo
                  alternative minimum commitments to substitute for Eyetech's
                  Minimum obligations if Raylo's failure to supply is due to
                  causes that Raylo eliminates and Raylo gives Eyetech
                  assurances to Eyetech's reasonable satisfaction that Raylo
                  will reliably satisfy any orders placed by Eyetech to meet
                  such alternative minimum commitments.

      3.3 Supply and Use of Eyetech Materials. Eyetech shall supply Raylo, at
least [**] days prior to the beginning of the first binding forecast period.,
with Eyetech Materials in sufficient amounts and adequate quality to permit
Raylo to meet its obligations above. The Parties acknowledge that failures by
Eyetech to meet such Eyetech Materials supply obligations may cause increases in
Raylo's costs of manufacturing API, and therefore the Parties agree to negotiate
in good faith adjustments to the API purchase price as necessary to compensate
Raylo for any such cost increases. Eyetech shall be responsible for shipping and
delivery of Eyetech Materials to Raylo. With respect to all Eyetech Materials,
Raylo shall: (a) at all times keep the Eyetech Materials secure and safe from
loss, damage, theft, misuse and unauthorized access in such manner as Raylo
stores its own proprietary materials of a similar nature, (b) maintain, store,
and handle the Eyetech Materials according to Eyetech's specifications and
current good manufacturing practice requirements (cGMP) and (c) dispose of
Eyetech Materials only in connection with Raylo's responsibilities under this
Agreement and otherwise follow Eyetech's instructions with regard to the
handling and disposition

                                       9
<PAGE>
of the Eyetech Materials. Title in and to the Eyetech Materials shall at all
times remain with Eyetech.

      3.4 Raw Materials; Annual List from Eyetech. Raylo shall be responsible
for the planning, procurement, testing, storage and release of the Raw
Materials. All Raw Materials purchased by Raylo shall meet cGMP and shall
conform to the specifications for such Raw Materials set forth in the
Specifications.

      3.5 cGMP Manufacture. Raylo will manufacture all API using the 15mM
Process in accordance with cGMP, the Specifications, Applicable Legal
Requirements, and all terms and conditions contained in the applicable Binding
Order (to the extent such terms and conditions are not inconsistent with this
Agreement), at the Facility.

      3.6 Raylo Services. Raylo shall diligently carry out the following
services (the "Services") in a professional and workmanlike manner:

            (a) Prepare, maintain and review all documents and records relating
to the manufacture of API, including without limitation all production records,
including master production and control records, and Batch production and
control records, in each case as required by and consistent with cGMP and the
Specifications.

            (b) Maintain a quality control unit in compliance with the FD&C Act,
including 21 CFR Section 211.22, and establish a procedure for communications
and interactions with Eyetech's quality control unit with respect to the
manufacture of the API.

            (c) Operate the Facility, including the supply of utilities, and
manufacture the API in conformance with the Specifications.

            (d) Provide, in accordance with a sampling plan to be established by
Eyetech and subject to the purchase price provisions of Section 4.1, API samples
and in-process samples for analysis and Batch release by Eyetech.

            (e) Review requirements (if any) for modifications to the 15mM
Process in order to meet the Specifications for manufacture of subsequent API
and notify Eyetech of such proposed modifications. Any such modifications to the
15mM Process are subject to approval by Eyetech.

            (f) Issue all Certificates.

      3.7 Facility.

            (a) Interim Cooperation at the Facility. In accordance with the LOU,
the Parties have agreed that Eyetech shall have certain supervisory involvement
relating to the processing of API at the Facility during an interim period that
commenced prior to the Effective Date. During such interim period, which shall
end on the LOU Termination Date, certain obligations of the Parties under this
Agreement shall be superseded and/or modified as set forth in the LOU.

                                       10
<PAGE>
            (b) Onsite Representative. Subsequent to the LOU Termination Date,
Raylo shall permit up to four (4) Eyetech employees, consultants and/or
representatives (which, at Eyetech's option, may include representatives of
Pfizer Inc.) to have reasonable access to the Facility during the manufacture of
the API, for the purpose of observing, reporting on, and consulting as to such
manufacturing efforts, including without limitation access to the review of all
batch records and documents. Raylo agrees to consider, in good faith, any
suggestions that Eyetech, or its onsite consultants/representatives, may have
regarding the design or operation of the Facility and shall, in all cases,
promptly respond to Eyetech regarding such suggestions.

                          4. PAYMENT AND PRICING TERMS

      4.1 API Purchase Price; Amendment of LOU. Raylo shall sell API to Eyetech
for the following prices and fees:

            (a) Prior to LOU Termination Date. Prior to the LOU Termination
Date, Eyetech shall pay Raylo the amounts set forth in the LOU.

            (b) After the LOU Termination Date. After the LOU Termination Date,
Raylo shall sell API manufactured using the 15mM Process to Eyetech at the
Negotiated Per Gram Cost as described in Exhibit D; provided that if, after the
LOU Termination Date, Eyetech determines that a change in the Specifications is
required, and such change increases Raylo's cost of production, the Parties
shall in good faith negotiate an amendment to this Agreement to compensate Raylo
for such increase to Raylo's cost of production.

            (c) Amendment of LOU. The Parties hereby amend the LOU to reflect
that the LOU shall terminate upon the completion of validation of the 15mM
Process pursuant to the Quality Agreement.

      4.2 Invoices. Invoices for the purchase price for API shall be delivered
to Eyetech no earlier than at the time of Delivery of such API. All properly
delivered invoices shall be paid by Eyetech within [**] days after Eyetech's
receipt thereof. In order to facilitate timely invoicing by Raylo, Eyetech
agrees that it will use commercially reasonable efforts to provide QC reports to
Raylo no later than [**] days after Raylo's delivery of samples to Eyetech for
testing.

      4.3 Amgen License Fee. If Eyetech exercises its option to obtain a license
under the Amgen Patents as set forth in Section 2.3(a), Eyetech shall pay to
Raylo [**].

      4.4 [**]License Fees. Eyetech shall reimburse Raylo for any license fees
and royalties paid by Raylo to [**] that are attributable to Raylo's supply of
API to Eyetech hereunder. Raylo shall invoice Eyetech for such license fees and
royalties after Raylo has paid them and shall include with such invoices
evidence of payment. Eyetech shall pay all such invoices within [**]) days after
Eyetech's receipt thereof.

                                       11
<PAGE>
      4.5 Currency. Raylo shall invoice Eyetech, and Eyetech shall pay Raylo,
all amounts hereunder in Canadian Dollars; provided that the [**], if payable,
shall be invoiced and paid in United States dollars.

      4.6 Taxes. All prices and charges are inclusive of all taxes, levies,
imposts, duties and fees of whatever nature imposed by or under the authority of
any government or public authority in respect of the Services and delivery of
API shall be paid by Raylo (other than any taxes on the income of Eyetech, which
shall be paid by Eyetech); provided that Eyetech shall be responsible for all
taxes, levies, imposts, duties and fees imposed by or under the authority of any
government or public authority in respect of the API (including any exportation
from Canada or importation into any other country) after Eyetech takes title to
API from Raylo.

                  5. REPRESENTATIONS, WARRANTIES AND COVENANTS

      5.1 Of Both Parties. Each Party warrants and represents as of the
Effective Date that such Party: (1) has the corporate power and authority to
enter into this Agreement; (2) is aware of no legal, contractual or other
restriction, limitation or condition that might affect adversely its ability to
perform hereunder; and (3) is in good standing under the laws of each
jurisdiction in which it is incorporated or engages in business activities.

      5.2 Of Raylo. Raylo represents, warrants and covenants to Eyetech that:

            (a) the Services shall be performed in accordance with this
Agreement and the Quality Agreement;

            (b) all API provided to Eyetech under this Agreement shall meet the
Specifications and shall be manufactured in accordance with cGMP;

            (c) unencumbered title to all API will be conveyed to Eyetech upon
payment by Eyetech of any invoices relating to such API;

            (d) the facilities (including, without limitation, the Facility) and
practices that shall be used in the performance of the Services and the
manufacture of the API shall conform to all Applicable Legal Requirements;

            (e) to the best of Raylo's knowledge and belief, Raylo has not, does
not and will not employ any individual who is debarred under Section 306 of the
FD&C Act and will provide a certification that it has not, does not and will not
use in any capacity the services of any person debarred under Section 306 of the
FD&C Act in connection with the manufacture of the API;

            (f) Raylo has obtained, and shall maintain during the term of this
Agreement, all required government permits, including but not limited to health,
safety and environmental permits, necessary for the conduct of the Services;

                                       12
<PAGE>
            (g) to the best of Raylo's knowledge and belief, Raylo's performance
of the Services and manufacture of the API will not infringe any rights
(including, without limitation, any intellectual property rights) of any third
party;

            (h) the information provided by Raylo to Eyetech pursuant to Section
2.2 shall be a complete and accurate in all material respects;

            (i) Raylo shall comply with any and all environmental requirements
in the performance of the Services and the manufacture of the API;

            (j) Raylo is the sole owner of the [**] Patents and has all rights
necessary to grant Eyetech the license set forth in Section 2.3(a); and

            (k) [**], as provided by Raylo to Eyetech prior to the Effective
Date, remains in full force and effect as of the Effective Date.

      5.3 Of Eyetech. Eyetech represents and warrants to Raylo that, to the best
of Eyetech's knowledge and belief, the Eyetech Materials provided by Eyetech for
use by Raylo in the manufacturing of API will not infringe or violate any valid
intellectual property rights of any third party.

      5.4 No Other Warranties. THE WARRANTIES CONTAINED IN THIS SECTION 5 ARE
EXPRESSLY IN LIEU OF AND EXCLUDE, AND THE PARTIES HEREBY EXPRESSLY DISCLAIM AND
NEGATE, ALL OTHER WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, ARISING BY
OPERATION OF LAW OR OTHERWISE, INCLUDING BUT NOT LIMITED TO, IMPLIED WARRANTIES
OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE AND
NON-INFRINGEMENT.

                                  6. COMPLAINTS

      6.1 Complaints Regarding API. In the event Eyetech has a complaint with
respect to API supplied to Eyetech, then:

            (a) If Eyetech's complaint concerns the quantity of such API,
Eyetech shall provide Raylo written notice of its complaint and provide
sufficient evidence to substantiate the short quantity. Upon receipt of such
written notice and substantiating evidence, Raylo shall supply to Eyetech as
promptly as practicable the said short quantity of such API. Such replacement
quantity shall be provided by Raylo at no additional cost to Eyetech, assuming
that Eyetech has already paid for such replacement quantity.

            (b) If Eyetech's complaint concerns the quality of such API
(non-compliance with the warranties set forth in Section 5 hereof), Eyetech
shall provide Raylo written notice of its complaint and provide sufficient
analytical evidence to substantiate the impairment. Upon receipt of such written
notice and substantiating evidence, the impaired amount of API shall be replaced
by Raylo with an equal amount of API conforming with the Specifications, as
promptly as practicable. Such replacement

                                       13
<PAGE>
quantity shall be provided by Raylo at no additional cost to Eyetech, assuming
that Eyetech has already paid for such replacement quantity.

            (c) Should Raylo disagree with the substantiating evidence provided
by Eyetech, Raylo shall supply the replacement quantity of API in accordance
with the terms of paragraphs (a) and (b) of this Section 6.1, and then both
Parties shall immediately and jointly carry out the necessary analysis to verify
whether Eyetech's complaint is justified. Should said analysis confirm the
validity of the complaint by Eyetech, then the matter shall be deemed
conclusively resolved. Should said analysis confirm the invalidity of the
complaint by Eyetech, then Raylo shall invoice Eyetech for the replacement
quantity provided in accordance with the terms of this Agreement.

      6.2 Recalls. If Eyetech undertakes a recall related to the API, Eyetech
shall notify Raylo. Raylo shall cooperate with and provide assistance to Eyetech
in connection with any such recall as reasonably requested by Eyetech.

      7. INDEMNIFICATION AND INSURANCE

      7.1 Indemnification.

            (a) By Raylo. Raylo shall indemnify, defend and hold harmless
Eyetech, its Affiliates, its sublicensees and distributors and their respective
directors, officers, employees and agents, from and against any and all
liabilities, damages, losses, costs or expenses whatsoever (including reasonable
legal fees and disbursements) arising out of or resulting from claims, demands,
or actions by third parties to the extent such liabilities, damages, losses,
costs or expenses arise from:

                  (1) any breach of Raylo's representations, warranties and
                  covenants set forth in Section 5; or

                  (2) personal injury (including death) or property damage
                  relating to or arising out of the failure by Raylo to
                  manufacture the API in accordance with cGMP and/or the
                  Specifications; or

                  (3) Raylo's violation of any environmental requirements in the
                  manufacture of API or performance of the Services.

            (b) By Eyetech. Eyetech shall indemnify, defend and hold harmless
Raylo, its Affiliates and their subcontractors, and their respective directors,
officers, employees and agents, from and against any and all liabilities,
damages, losses, costs or expenses whatsoever (including reasonable legal fees
and disbursements) arising out of or resulting from claims, demands, or actions
by third parties to the extent such liabilities, damages, losses, costs or
expenses arise from:

                  (1) any breach of Eyetech's representations and warranties set
                  forth in Section 5; or

                                       14
<PAGE>
                  (2) personal injury (including death) or property damage
                  relating to or arising out of any manufacture, use,
                  distribution or sale of the Eyetech Product by Eyetech, its
                  Affiliates or its sublicensees; except, in each case, to the
                  extent that Raylo is indemnifying Eyetech in accordance with
                  Section 7.1(a)(2) above.

      7.2 Procedure for Indemnification. In the event that any person (an
"Indemnified Party") entitled to indemnification under Section 7.1(a) or 7.1(b)
is seeking such indemnification, such Indemnified Party shall promptly notify
the indemnifying Party (the "Indemnitor") in writing of the claim (and in
reasonable detail); provided, however, that failure to give such notification
shall not affect the indemnification to be provided hereunder except to the
extent the Indemnitor shall have been actually prejudiced as a result of such
failure. The Indemnitor shall manage and control, at its sole expense, the
defense of the claim and its settlement. The Indemnified Party shall provide the
Indemnitor, at the Indemnitor's cost, with reasonable assistance and relevant
information to support the defense of any such claim. The Indemnitor shall not
accept any settlement which imposes liability not covered by this
indemnification or impose any obligation on, or otherwise adversely affect, the
Indemnified Party or other Party without the prior written consent of such
Indemnified Party or other Party, as applicable. Nothing contained in this
Section 7.2 shall oblige the Indemnified Party to take any action or steps in
its own name in defending any claim, action or proceedings; however, the
Indemnified Party, at is option and expense, may review and comment on the
defense of any claim through its own counsel; provided that the Indemnitor shall
be responsible for the fees and costs of the Indemnified Party's counsel if: (1)
the Indemnitor and the Indemnified Party shall have mutually agreed to the
retention of such counsel; (2) the Indemnified Party shall have reasonably
concluded that there may be one or more legal defenses available to it which are
different from or additional to those available to the Indemnitor; or (3) the
named parties to any such proceeding (including the impleaded parties) include
both the Indemnitor and the Indemnified Party, and representation of both
parties by the same counsel would be inappropriate in the opinion of the
Indemnified Party's counsel due to actual or potential differing interests
between them; in any such case, one (1) firm of attorneys separate from the
Indemnitor's counsel may be retained to represent the Indemnified Party at the
Indemnitor's expense. As the Parties intend complete indemnification, all costs
and expenses incurred by an Indemnified Party in connection with enforcement of
Sections 7.1(a) or (b) shall also be reimbursed by the Indemnitor.

      7.3 Insurance. Raylo shall obtain and maintain during the term of this
Agreement: (1) comprehensive general liability insurance on a claims made basis,
with coverage limits of not less than US$5 million per claim and US$20 million
aggregate and (2) property insurance which includes business interruption
coverage. Raylo shall name Eyetech as an additional insured on its policies. The
minimum level of insurance set forth herein shall not be construed to create a
limit on Raylo's liability hereunder. Within thirty (30) days after the
Effective Date, Raylo shall furnish to Eyetech a certificate of insurance
evidencing such coverage. Each such certificate of insurance, as well as any
certificates evidencing new or modified coverages of Raylo, shall include a
provision whereby thirty (30) days written notice must be received by Eyetech
prior to coverage modification, and ten (10) days written notice must be
received by Eyetech prior to

                                       15
<PAGE>
coverage cancellation, by either Raylo or the insurer. In addition, Raylo shall
promptly notify Eyetech of any cancellation or modification of such insurance
coverage and of any new or modified coverage. In the case of a modification or
cancellation of such coverage, Raylo shall promptly provide Eyetech with a new
certificate of insurance evidencing that Raylo's coverage meets the requirements
in the first sentence of this Section 7.3.

                 8. LIMITATION OF LIABILITY; LIQUIDATED DAMAGES.

      8.1 EXCEPT WITH RESPECT TO (i) RAYLO BREACHING ITS CONFIDENTIALITY
OBLIGATIONS UNDER SECTION 10 HEREOF, AND (ii) EYETECH'S COSTS OF PROCURING
ALTERNATE SUPPLY OF API IF RAYLO FAILS TO MEET ITS OBLIGATIONS TO SUPPLY API
HEREUNDER, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR
SPECIAL, INCIDENTAL, CONSEQUENTIAL, EXEMPLARY, PUNITIVE, MULTIPLE OR OTHER
INDIRECT DAMAGES, OR FOR LOSS OF PROFITS, LOSS OF DATA OR LOSS OF USE DAMAGES,
ARISING OUT OF THE MANUFACTURE, SALE, SUPPLYING OR FAILURE OR DELAY IN SUPPLYING
OF THE API OR EYETECH PRODUCT OR OTHERWISE ARISING OUT OF THIS AGREEMENT,
WHETHER BASED UPON WARRANTY, CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, EVEN
IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR LOSSES.

      8.2 NOTHING IN THIS SECTION 8 IS INTENDED TO LIMIT OR RESTRICT THE
INDEMNIFICATION OBLIGATIONS OF RAYLO UNDER THIS AGREEMENT WITH RESPECT TO THIRD
PARTY CLAIMS UNDER SECTION 7.

                                 9. TERMINATION.

      9.1 Initial Term; Extensions. This Agreement shall take effect as of the
Effective Date and shall, unless sooner terminated pursuant to this Section 9,
remain in effect until November 11, 2008 (the "Initial Term"). Upon written
notice from Eyetech to Raylo on or before six (6) months prior to the expiration
of the Initial Term, Eyetech shall have the right to extend the term of this
Agreement for a period of up to three (3) years, as determined by Eyetech in its
discretion. Eyetech shall specify the number of years for such extension in the
notice provided to Raylo under this Section 9.1. Upon written notice to Raylo
not later than six (6) months prior to the expiration of the term as extended by
Eyetech pursuant to this Section 9.1, Eyetech shall have the further right to
extend of the term of this Agreement for an additional period of up to three (3)
years. Eyetech shall specify the number of years for such extension in the
notice provided to Raylo under this Section 9.1.

      9.2 Termination by Eyetech.

            (a) Eyetech Product Failure. Eyetech shall have the right to
terminate this Agreement immediately, upon written notice, if Eyetech elects to
abandon its efforts to commercialize the Eyetech Product.

                                       16
<PAGE>

            (b) Failure to Obtain Licenses to Third Party Patent Rights. Eyetech
shall have the right to terminate this Agreement immediately, upon written
notice, if Raylo has not obtained all licenses to third party Patent Rights
necessary to enable Eyetech to use and offer for sale the API in, and to import
the API into, the United States and any other country in which the Amgen
Patents [**] are in force.

            (c) Nonoccurrence of the LOU Termination Date. Eyetech shall have
the right to terminate this Agreement and the LOU immediately, upon written
notice, if the LOU Termination Date has not occurred on or before January 1,
2005.

            (d) Regulatory Changes and Infractions. Eyetech shall have the right
to terminate this Agreement if the (i) United Stated Food and Drug
Administration imposes requirements that require a change in the Specifications
that, in Eyetech's judgment, Raylo cannot accommodate to Eyetech's reasonable
satisfaction or (ii) Raylo is unable to Deliver Eyetech's requirements of API
due to violation of any Applicable Legal Requirements.

            (e) Change in Control of Raylo. In the event that any Person (other
than Raylo, any trustee or other fiduciary holding securities under an employee
benefit plan of Raylo, or any corporation owned directly or indirectly by the
stockholders of Raylo in substantially the same proportion as their ownership of
stock of Raylo) is or becomes the "beneficial owner" (as defined in Rule 13d-3
under the Securities Exchange Act of 1934, as amended), directly or indirectly,
of securities of Raylo representing greater than 50% of the combined voting
power of Raylo's then outstanding securities (a "Change in Control"), Eyetech
may terminate this Agreement upon thirty (30) days' written notice given to
Raylo at any time within six (6) months after such Change in Control.

            (f) Competitive Pricing. In the event that at any time during the
Term after December 31, 2005, a third party other than Pfizer Inc. or an
affiliate of Pfizer Inc. is able to manufacture API in accordance with the
Specifications and cGMP, in at least the same quantities as those manufactured
by Raylo hereunder and at a cost that is less than the price for the API
currently charged Eyetech by Raylo, then Raylo shall have [**] days in which to
reduce its price for the API to the price to be charged Eyetech by such third
party; provided that if the third party with which Eyetech proposes to enter
into such lower-cost arrangement would use a higher volume or different process
than a 15mM process and Raylo agrees in writing to develop a higher volume or
different process in order to achieve the required cost reduction, then Raylo
shall have an additional [**] days (i.e., a total of [**] days) in which to
reduce its price for the API to the price to be charged Eyetech by such third
party. If Raylo fails to lower its prices, Eyetech shall have the right to
terminate this Agreement immediately, upon written notice; provided that orders
made by Eyetech prior to such termination would be filled by Raylo, and paid for
by Eyetech, in accordance with the terms of this Agreement.

      9.3 Termination for Breach; Insolvency. Either Raylo or Eyetech may
terminate this Agreement immediately, without prejudice to any other remedies
available

                                       17
<PAGE>
to it at law or in equity, by notice in writing to the other upon the occurrence
of any of the following events:

            (a) If the other Party (the "Breaching Party") materially breaches
this Agreement, and such breach is not remedied within sixty (60) days after
receipt by the Breaching Party of notice identifying the breach; or

            (b) If the other Party ceases for any reason to carry on business,
dissolves, liquidates, winds up, or files or is petitioned into bankruptcy,
liquidation, rehabilitation or dissolution or becomes insolvent or fails
generally to pay its debts or obligations or a petition is filed seeking the
appointment of or the taking possession by a receiver, custodian, trustee or
similar official.

      9.4 Effect of Expiration or Termination. Upon the expiration of this
Agreement at the end of the Term, or upon the termination of this Agreement by
either Party pursuant to this Section 9:

            (a) Raylo shall promptly: (i) return to Eyetech all relevant
records, materials or Eyetech Confidential Information (to the extent legal or
regulatory requirements permit), including, without limitation, all
manufacturing records relating to the API; (ii) return to Eyetech the Eyetech
Materials then in the possession or control of Raylo or its Affiliates; and
(iii) discontinue all manufacture of the API;

            (b) Eyetech shall promptly return to Raylo all Raylo Confidential
Information (to the extent legal or regulatory requirements permit);

            (c) The licenses granted under Section 2.3(a) and (c) shall survive
termination and the licenses granted under Section 2.3(b) shall not;

            (d) At Eyetech's request, and at Eyetech's expense or the expense of
Eyetech's designated second or alternative source manufacturer of API, Raylo
shall exercise its right under Section 2.02 of the [**] to grant a license on
terms [**] designated by Eyetech at any time prior to the first anniversary of
the expiration or termination of this Agreement;

            (e) At Eyetech's request and at Eyetech's expense, Raylo shall
provide Eyetech with reasonable assistance in transferring the manufacturing
activities covered by this Agreement to a third party contract manufacturer; and

            (f) At Eyetech's request, Raylo shall sell to Eyetech all (i)
inventory of Raw Materials then in Raylo's possession, at Raylo's out-of-pocket
costs incurred in the procurement of such Raw Materials, (ii) work-in-process
then in Raylo's possession, at a pro rated portion of the Negotiated Per Gram
Cost reflecting Raylo's out-of-pocket costs and the work performed by Raylo
prior to transfer, and (iii) API then in Raylo's possession, at the Negotiated
Per Gram Cost.

      9.5 Survival. The expiration or prior termination of this Agreement for
whatever reason shall not affect the accrued rights of either Raylo or Eyetech
arising

                                       18
<PAGE>
under this Agreement and Sections 2.3(a), 2.3(c), 2.3(d), 6, 7, 8, 9, 10 and 11
shall survive such expiration or termination.

                               10. CONFIDENTIALITY

      10.1 Confidential Information. Each Party agrees that all Confidential
Information disclosed to it or its Affiliates by the other Party (a) shall not
be used by the receiving Party or its Affiliates except in connection with the
activities contemplated by this Agreement or in order to further the purposes of
this Agreement and, for the avoidance of doubt, shall not be used by the
receiving Party in connection with products or services other than the API or
the manufacture thereof, (b) shall be maintained in confidence by the receiving
Party and its Affiliates, and (c) shall not be disclosed by the receiving Party
or its Affiliates to any third party who is not an Affiliate or consultant of,
or an advisor to, the receiving Party or its Affiliates without the prior
written consent of the disclosing Party. Notwithstanding the foregoing
provisions of this Section 10.1, (x) either Party may disclose Confidential
Information of the other Party if such Party is required to make such disclosure
by applicable law, regulation or legal process, including without limitation by
the rules or regulations of the United States Securities and Exchange Commission
(the "SEC") or similar regulatory agency in a country other than the United
States or of any stock exchange or Nasdaq, in which event such Party shall
provide prior notice of such intended disclosure to such other Party if possible
under the circumstances and shall disclose only such Confidential Information of
such other Party as is required to be disclosed and (y) the Parties (and each
employee, representative, or other agent of the Parties) may disclose to any and
all Persons, without limitation of any kind, the United States federal tax
treatment and tax structure of the transactions set forth in this Agreement and
all materials of any kind (including opinions or other tax analyses) that are
provided to the Parties relating to such tax treatment and tax structure.

      10.2 Disclosures to Employees, Consultants, Advisors, Agents and
Subcontractors. Each Party agrees that it and its Affiliates shall provide
Confidential Information received from the other Party only to the receiving
Party's respective employees, consultants, advisors, agents and subcontractors
and to the employees, consultants, advisors, agents and subcontractors of the
receiving Party's Affiliates, who have a need to know such Confidential
Information to assist the receiving Party in fulfilling its obligations under
this Agreement, provided that Eyetech and Raylo shall each remain responsible
for any failure by its and its Affiliates' respective employees, consultants,
advisors, agents and subcontractors to treat such information and materials as
required under Section 10.1.

      10.3 Term. All obligations of confidentiality imposed under Sections 10.1
and 10.2 shall expire upon the later of (a) expiration or termination of this
Agreement and (b) five (5) years after the date the applicable Confidential
Information is disclosed.

                             11. GENERAL PROVISIONS

      11.1 Independent Status of Parties. Each Party shall act as an independent
contractor and shall not bind nor attempt to bind the other Party to any
contract, or any

                                       19
<PAGE>
performance of obligations outside of this Agreement. Nothing contained or done
under this Agreement shall be interpreted as constituting either Party the
agent, partner or joint venturer of the other in any sense of the term
whatsoever unless expressly so stated.

      11.2 Subcontracting. Raylo shall have the right to wholly or partly
subcontract the activities to be performed by Raylo hereunder, provided,
however, that (a) said subcontractor shall be approved in advance by Eyetech,
such approval not to be unreasonably withheld, and (b) Raylo shall remain fully
responsible for all of its obligations hereunder.

      11.3 Publicity. Neither Party shall originate any publicity, news release
or other public announcement, written or oral, relating to this Agreement
without the prior written approval of the other Party except as otherwise
required by law. Such approval shall not be unreasonably withheld. Upon approval
and launch of the Eyetech Product, Eyetech will allow Raylo to publicly announce
that Raylo is a manufacturer of API for Eyetech.

      11.4 Governing Law. This Agreement shall be governed by and interpreted in
accordance with, and any arbitration or court action hereunder shall apply, the
laws of the State of New York, excluding (i) its conflicts of laws principles,
(ii) the United Nations Convention on Contracts for the International Sale of
Goods, (iii) the 1974 Convention on the Limitation Period in the International
Sale of Goods (the "1974 Convention"); and (iv) the protocol amending the 1974
Convention, done at Vienna April 11, 1980.

      11.5 Dispute Resolution. Any dispute arising out of or relating to this
Agreement shall be resolved through binding arbitration as follows:

            (a) A Party may submit such dispute to arbitration by notifying the
other Party, in writing, of such dispute. Within thirty (30) days after receipt
of such notice, the Parties shall designate in writing a single arbitrator to
resolve the dispute; provided, however, that if the Parties cannot agree on an
arbitrator within such 30-day period, the arbitrator shall be selected by the
Minneapolis, Minnesota, USA office of the American Arbitration Association (the
"AAA"). The arbitrator shall be a lawyer with biotechnology and/or
pharmaceutical industry legal experience, and shall not be an Affiliate,
employee, consultant, officer, director or stockholder of any Party.

            (b) Within thirty (30) days after the designation of the arbitrator,
the arbitrator and the Parties shall meet, at which time the Parties shall be
required to set forth in writing all disputed issues and a proposed ruling on
the merits of each such issue.

            (c) The arbitrator shall set a date for a hearing, which shall be no
later than forty-five (45) days after the submission of written proposals
pursuant to Section 11.5(b), to discuss each of the issues identified by the
Parties. The Parties shall have the right to be represented by counsel. Except
as provided herein, the arbitration shall be governed by the Commercial
Arbitration Rules of the AAA; provided, however, that the Federal Rules of
Evidence shall apply with regard to the admissibility of evidence and the
arbitration shall be conducted by a single arbitrator.

                                       20
<PAGE>
            (d) The arbitrator shall use his or her best efforts to rule on each
disputed issue within thirty (30) days after the completion of the hearings
described in Section 11.5(c). The determination of the arbitrator as to the
resolution of any dispute shall be binding and conclusive upon all Parties. All
rulings of the arbitrator shall be in writing and shall be delivered to the
Parties.

            (e) The (i) attorneys' fees of the Parties in any arbitration, (ii)
fees of the arbitrator and (iii) costs and expenses of the arbitration shall be
borne by the Parties as determined by the arbitrator.

            (f) Any arbitration pursuant to this Section 11.5 shall be conducted
in Minneapolis, Minnesota, USA. Any arbitration award may be entered in and
enforced by any court of competent jurisdiction.

      11.6 No Limitation. Nothing in Section 11.5 shall be construed as limiting
in any way the right of a Party to seek an injunction or other equitable relief
with respect to any actual or threatened breach of this Agreement or to bring an
action in aid of arbitration. Should any Party seek an injunction or other
equitable relief, or bring an action in aid of arbitration, then for purposes of
determining whether to grant such injunction or other equitable relief, or
whether to issue any order in aid of arbitration, the dispute underlying the
request for such injunction or other equitable relief, or action in aid of
arbitration, may be heard by the court in which such action or proceeding is
brought.

      11.7 Notices. All notices, instructions and other communications hereunder
or in connection herewith shall be in writing and shall be (a) delivered
personally, (b) sent by registered or certified mail, return receipt requested,
postage prepaid, (c) sent via a reputable nationwide overnight courier service,
or (d) sent by facsimile transmission, in each case to an address set forth
below. Any such notice, instruction or communication shall be deemed to have
been delivered upon receipt if delivered by hand, three Business Days after it
is sent by registered or certified mail, return receipt requested, postage
prepaid, one Business Day after it is sent via a reputable nationwide overnight
courier service, or when transmitted with electronic confirmation of receipt, if
transmitted by facsimile with confirmed answerback (if such transmission is on a
Business Day; otherwise, on the next day following such transmission).

      Notices to Raylo shall be addressed to     Raylo Chemicals, Inc.
                                                 8045 Argyll Road
                                                 Edmonton, Alberta
                                                 Canada T6C 4A9
                                                 Phone:  (780) 468-6060
                                                 Fax:  (780) 472-8189
                                                 Attn:  Matt Colomb

      Notices to Eyetech shall be addressed to   Eyetech Pharmaceuticals, Inc.
                                                 500 Seventh Avenue, 18th Floor
                                                 New York, New York 10018

                                       21
<PAGE>
                                                 Phone:  (212) 997-9241
                                                 Fax:  (212) 997-9251
                                                 Attn:  Chief Executive Officer

      With a copy to:                            Eyetech Pharmaceuticals, Inc.
                                                 500 Seventh Avenue, 18th Floor
                                                 New York, New York 10018
                                                 Phone: (212) 997-9241
                                                 Fax: (212) 997-9251
                                                 Attn: General Counsel

      Either Party may change its address by giving notice to the other Party in
the manner herein provided.

      11.8 Entire Agreement. This Agreement, the LOU and the Quality Agreement
collectively contain the full understanding of the Parties with respect to the
subject matter hereof and supersede all prior understandings and writings
relating thereto. No waiver, alteration or modification of any of the provisions
of such agreements shall be binding unless made in writing and signed by the
Parties.

      11.9 Headings. The headings contained in this Agreement are for
convenience of reference only and shall not be considered in construing this
Agreement.

      11.10 Severability. If, under applicable law or regulation, any provision
of this Agreement is invalid or unenforceable, or otherwise directly or
indirectly affects the validity of any other material provision(s) of this
Agreement (such invalid or unenforceable provision, a "Severed Clause"), this
Agreement shall endure except for the Severed Clause. The Parties shall consult
one another and use reasonable efforts to agree upon a valid and enforceable
provision that is a reasonable substitute for the Severed Clause in view of the
intent of this Agreement.

      11.11 Assignment. Neither this Agreement nor any of the rights or
obligations hereunder may be assigned by either Party without the prior written
consent of the other Party, except to an Affiliate of the assigning Party or to
any party who acquires all or substantially all of the capital stock or assets
of the assigning Party related to the transactions contemplated in this
Agreement by merger, consolidation, sale of assets or otherwise, so long as such
Affiliate or other party agrees in writing to be bound by the terms of this
Agreement.

      11.12 Performance by Affiliates. To the extent that this Agreement imposes
obligations on Affiliates of a Party, such Party agrees to cause its Affiliates
to perform such obligations. Either Party may use one or more of its Affiliates
to perform its obligations and duties hereunder, provided that the Parties shall
remain liable hereunder for the prompt payment and performance of all their
respective obligations hereunder.

      11.13 Successors and Assigns. This Agreement shall be binding upon and
inure to the benefit of the Parties hereto and their successors and permitted
assigns.

                                       22
<PAGE>
      11.14 Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be deemed an original but all of such together
shall constitute one and the same instrument.

                                       23
<PAGE>
      IN WITNESS WHEREOF, the Parties hereto have caused this Manufacturing and
Supply Agreement to be executed in their names by their properly and duly
authorized officers or representatives as of the date first above written.

RAYLO CHEMICALS, INC.                     EYETECH PHARMACEUTICALS, INC.

By:     /s/J.Matthew Colab                By:    /s/Paul G. Chaney
   ------------------------------------      -----------------------------------
Name:                                     Name:  Paul G. Chaney
Title:  President                         Title: COO

November 11, 2003

                                       24
<PAGE>
                                    Exhibit A

                                 Specifications

--------------------------------------------------------------------------------
                                                                   2880
                                                                   ----

RAYLO                                                          Form No A009
CHEMICALS                      [**]                            Issue       6

Product/Intermediate     Supercedes       Effective Date     Page 1 of 2
Specification                    None     June 18, 2002

--------------------------------------------------------------------------------

Test                              Test Method                   Limit

--------------------------------------------------------------------------------

                                      [**]

Sampling Instructions:     [**]
Sample Size:               [**]      Reserve Sample:  [**]  Biosample Size: [**]
Storage Conditions:        [**]      Sample Retention Time:     [**]
Release Validity Period:   [**]      Sample Disposal:           [**]

--------------------------------------------------------------------------------
APPROVED BY                      SIGNATURE                         DATE

QUALITY CONTROL GROUP            [ILLEGIBLE]                       May 29, 2002
LABORATORY GROUP                 [ILLEGIBLE]                       May 31, 2002
MANUFACTURING GROUP              [ILLEGIBLE]                       May 31, 2002
QUALITY ASSURANCE GROUP          [ILLEGIBLE]                       June 18, 2002
--------------------------------------------------------------------------------

                                       25
<PAGE>
--------------------------------------------------------------------------------
                                                                   2880
                                                                   ----

RAYLO                                                          Form No A009
CHEMICALS                      [**]                            Issue       6

Product/Intermediate     Supercedes       Effective Date     Page 2 of 2
Specification                    None     June 18, 2002

--------------------------------------------------------------------------------

CHEMICAL FORMULA                        STRUCTURAL FORMULA

    [**]                                [**]

PHYSICAL DATA

    [**]

[**]

================================================================================

                                       26
<PAGE>
                                    Exhibit B

                                Eyetech Materials

<TABLE>
<CAPTION>
---------------------------------------------------------------------------------------------------------------
Raylo Spec Number      Company         Specification Name          Common       u/m             Quantity Breaks
                                                                    Name
---------------------------------------------------------------------------------------------------------------
<S>                    <C>             <C>                         <C>          <C>             <C>

[**]
</TABLE>

                                       27
<PAGE>
                                    Exhibit C

                                    Minimums

<TABLE>
<CAPTION>
2004              2005             2006              2007              2008
<S>               <C>              <C>               <C>               <C>
100%              100%             [**]%             [**]%             [**]%
</TABLE>

                                       28
<PAGE>
                                    Exhibit D

                            Negotiated Per Gram Cost

      Per gram pricing shall be based on the following assumptions and formula:

Maximum [**]:

      Will be based on the [**].

[**]:

      Will be the [**] during the life of this agreement [**].

[**]:

      Will initially be the [**]

[**]:

      Will be [**] hereunder.

[**]:

      Will initially be [**].

      [**]. However, should Eyetech [**].

      [**] Raylo will [**].

[**]:

         Will initially be [**].

[**]:

      Shall be [**]:

      1- In calculation of [**].

      2- In calculation for [**].

      3- In calculation of [**].

      4- In calculation of [**].

The Formula for Per Gram Cost [**] will be in $ per gram:

                                      [**]
--------------------------------------------------------------------------------
                                      [**]

                                       29
<PAGE>
                                   Exhibit D-1

              Areas of Facility Dedicated to Production for Eyetech

           [Floor plan of the area divided into work and office space]

                                       30

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00060-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00060-of-00352.parquet"}]]